Keywords: Intercept Pharma, Servier, TGR5 program, Type 2 diabetes

Intercept Pharma in $163 million deal with Servier for TGR5 program in type 2 diabetes

Article | 10 August 2011

New York, USA-based Intercept Pharmaceuticals has entered into a worldwide ex-USA and Japan agreement with privately-owned French drugmaker Laboratoires Servier ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Servier

Intercept Pharmaceuticals

Go to company listing